349 related articles for article (PubMed ID: 17651783)
1. High levels of the p53 inhibitor MDM4 in head and neck squamous carcinomas.
Valentin-Vega YA; Barboza JA; Chau GP; El-Naggar AK; Lozano G
Hum Pathol; 2007 Oct; 38(10):1553-62. PubMed ID: 17651783
[TBL] [Abstract][Full Text] [Related]
2. The expression of MDM2, MDM4, p53 and p21 in myeloid neoplasms and the effect of MDM2/MDM4 dual inhibitor.
Eskandari M; Shi Y; Liu J; Albanese J; Goel S; Verma A; Wang Y
Leuk Lymphoma; 2021 Jan; 62(1):167-175. PubMed ID: 32924682
[TBL] [Abstract][Full Text] [Related]
3. MDM2 and MDM4: p53 regulators as targets in anticancer therapy.
Toledo F; Wahl GM
Int J Biochem Cell Biol; 2007; 39(7-8):1476-82. PubMed ID: 17499002
[TBL] [Abstract][Full Text] [Related]
4. Dual inhibition of MDM2 and MDM4 in virus-positive Merkel cell carcinoma enhances the p53 response.
Park DE; Cheng J; Berrios C; Montero J; Cortés-Cros M; Ferretti S; Arora R; Tillgren ML; Gokhale PC; DeCaprio JA
Proc Natl Acad Sci U S A; 2019 Jan; 116(3):1027-1032. PubMed ID: 30598450
[TBL] [Abstract][Full Text] [Related]
5. Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53.
Parant J; Chavez-Reyes A; Little NA; Yan W; Reinke V; Jochemsen AG; Lozano G
Nat Genet; 2001 Sep; 29(1):92-5. PubMed ID: 11528400
[TBL] [Abstract][Full Text] [Related]
6. Analysis of human MDM4 variants in papillary thyroid carcinomas reveals new potential markers of cancer properties.
Prodosmo A; Giglio S; Moretti S; Mancini F; Barbi F; Avenia N; Di Conza G; Schünemann HJ; Pistola L; Ludovini V; Sacchi A; Pontecorvi A; Puxeddu E; Moretti F
J Mol Med (Berl); 2008 May; 86(5):585-96. PubMed ID: 18335186
[TBL] [Abstract][Full Text] [Related]
7. Rare MDM4 gene amplification in colorectal cancer: The principle of a mutually exclusive relationship between MDM alteration and TP53 inactivation is not applicable.
Suda T; Yoshihara M; Nakamura Y; Sekiguchi H; Godai TI; Sugano N; Tsuchida K; Shiozawa M; Sakuma Y; Tsuchiya E; Kameda Y; Akaike M; Matsukuma S; Miyagi Y
Oncol Rep; 2011 Jul; 26(1):49-54. PubMed ID: 21503588
[TBL] [Abstract][Full Text] [Related]
8. A mouse p53 mutant lacking the proline-rich domain rescues Mdm4 deficiency and provides insight into the Mdm2-Mdm4-p53 regulatory network.
Toledo F; Krummel KA; Lee CJ; Liu CW; Rodewald LW; Tang M; Wahl GM
Cancer Cell; 2006 Apr; 9(4):273-85. PubMed ID: 16616333
[TBL] [Abstract][Full Text] [Related]
9. MDM2 but not MDM4 promotes retinoblastoma cell proliferation through p53-independent regulation of MYCN translation.
Qi DL; Cobrinik D
Oncogene; 2017 Mar; 36(13):1760-1769. PubMed ID: 27748758
[TBL] [Abstract][Full Text] [Related]
10. XI-011 enhances cisplatin-induced apoptosis by functional restoration of p53 in head and neck cancer.
Roh JL; Park JY; Kim EH
Apoptosis; 2014 Nov; 19(11):1594-602. PubMed ID: 25113507
[TBL] [Abstract][Full Text] [Related]
11. Estrogen receptor alpha (ERα/ESR1) mediates the p53-independent overexpression of MDM4/MDMX and MDM2 in human breast cancer.
Swetzig WM; Wang J; Das GM
Oncotarget; 2016 Mar; 7(13):16049-69. PubMed ID: 26909605
[TBL] [Abstract][Full Text] [Related]
12. High-resolution array-based comparative genomic hybridization of bladder cancers identifies mouse double minute 4 (MDM4) as an amplification target exclusive of MDM2 and TP53.
Veerakumarasivam A; Scott HE; Chin SF; Warren A; Wallard MJ; Grimmer D; Ichimura K; Caldas C; Collins VP; Neal DE; Kelly JD
Clin Cancer Res; 2008 May; 14(9):2527-34. PubMed ID: 18451213
[TBL] [Abstract][Full Text] [Related]
13. Amplification and overexpression of the MDM4 (MDMX) gene from 1q32 in a subset of malignant gliomas without TP53 mutation or MDM2 amplification.
Riemenschneider MJ; Büschges R; Wolter M; Reifenberger J; Boström J; Kraus JA; Schlegel U; Reifenberger G
Cancer Res; 1999 Dec; 59(24):6091-6. PubMed ID: 10626796
[TBL] [Abstract][Full Text] [Related]
14. Augmented antitumor activity of 5-fluorouracil by double knockdown of MDM4 and MDM2 in colon and gastric cancer cells.
Imanishi M; Yamamoto Y; Wang X; Sugaya A; Hirose M; Endo S; Natori Y; Yamato K; Hyodo I
Cancer Sci; 2019 Feb; 110(2):639-649. PubMed ID: 30488540
[TBL] [Abstract][Full Text] [Related]
15. Mdm4 and Mdm2 cooperate to inhibit p53 activity in proliferating and quiescent cells in vivo.
Francoz S; Froment P; Bogaerts S; De Clercq S; Maetens M; Doumont G; Bellefroid E; Marine JC
Proc Natl Acad Sci U S A; 2006 Feb; 103(9):3232-7. PubMed ID: 16492744
[TBL] [Abstract][Full Text] [Related]
16. The MDM2 gene family.
Mendoza M; Mandani G; Momand J
Biomol Concepts; 2014 Mar; 5(1):9-19. PubMed ID: 25372739
[TBL] [Abstract][Full Text] [Related]
17. Analysis of the K-ras and p53 pathways in X-ray-induced lung tumors in the rat.
Belinsky SA; Middleton SK; Picksley SM; Hahn FF; Nikula KJ
Radiat Res; 1996 Apr; 145(4):449-56. PubMed ID: 8600505
[TBL] [Abstract][Full Text] [Related]
18. Mouse models of Mdm2 and Mdm4 and their clinical implications.
Xiong S
Chin J Cancer; 2013 Jul; 32(7):371-5. PubMed ID: 23327795
[TBL] [Abstract][Full Text] [Related]
19. MAGE-A Cancer/Testis Antigens Inhibit MDM2 Ubiquitylation Function and Promote Increased Levels of MDM4.
Marcar L; Ihrig B; Hourihan J; Bray SE; Quinlan PR; Jordan LB; Thompson AM; Hupp TR; Meek DW
PLoS One; 2015; 10(5):e0127713. PubMed ID: 26001071
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the chemosensitivity of head and neck cancer cells based on the diverse function of mutated-p53.
Shinagawa Y; Kawamata H; Omotehara F; Nakashiro K; Hoque MO; Furihata T; Horiuchi H; Imai Y; Fujimori T; Fujibayashi T
Int J Oncol; 2003 Feb; 22(2):383-9. PubMed ID: 12527938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
